Interventions: VK2735 Primary Outcome Measure: Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment Time Frame: 78 weeks Study Details Source VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) Sponsor: Viking Therapeutics Goal: This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
In the research setting, tirzepatyd is used to assess receptor affinity, activation of intracellular signalling cascades and the interplay between GIP and GLP-1 receptors, both in vitro and in non-human experimental models
AhK: Conceptualization, Formal analysis, Methodology, Visualization, Writing original draft, Writing review & editing
Mol Neurobiol (2019) 56(10):675669